

**ANFIELD  
SUJIR  
KENNEDY  
& DURNO**

BARRISTERS & SOLICITORS



1600 - 609 GRANVILLE STREET  
P.O. BOX 10068 PACIFIC CENTRE  
VANCOUVER, B.C. V7Y 1C3

TELEPHONE: (604) 669-1322  
FACSIMILE: (604) 669-3877

REPLY TO THE ATTENTION OF: Michael Kennedy  
E-MAIL: mkennedy@askdlaw.com

OUR FILE NUMBER: MK/7248

May 7, 2004


VIA: COURIER

United States Securities and Exchange Commission  
450 Fifth Street, N.W.  
Washington, D.C. 20549

Dear Sirs/Mesdames:

**Re: BioMS Medical Corp. (the "Issuer")**  
**Submission Pursuant to Rule 12g3-2(b) under the United States Security Act of 1934**  
**Your File No. 82-3468-9**

**SUPPL**  
**PROCESSED**  
**MAY 17 2004**  
**THOMSON  
FINANCIAL**



Further to the above-captioned matter, please find enclosed the following relevant documents since the date of the Issuer's previous submission:

INFORMATION REFERRED TO IN SECTION (b)(1)(a)(i)		WHEN IT IS REQUIRED TO BE MADE PUBLIC	BY WHOM IT IS REQUIRED TO BE MADE PUBLIC, FILED WITH ANY SUCH EXCHANGE, OR DISTRIBUTED TO SECURITY HOLDERS
1.	Information which the Issuer has made or is required to make public since March 2004 (date of most recent submission) pursuant to the laws of Canada:		
a.	news releases	Immediately	Issuer
	i. March 18, 2004		
	ii. March 23, 2004		
b.	material change reports within 10 days of the material change (date indicated is date of material change to which report relates)		Issuer
	i. March 18, 2004		

*Handwritten signature/initials*

**ANFIELD SUJIR KENNEDY & DURN O**

US SEC

May 7, 2004


Page 2

INFORMATION REFERRED TO IN SECTION (b)(1)(a)(i)	WHEN IT IS REQUIRED TO BE MADE PUBLIC	BY WHOM IT IS REQUIRED TO BE MADE PUBLIC, FILED WITH ANY SUCH EXCHANGE, OR DISTRIBUTED TO SECURITY HOLDERS
2. Information which the Issuer has filed or is required to file with The Toronto Stock Exchange:  a. the same information as referred to in items 1.a and b above		
3. Materials which the Issuer has distributed or is required to distribute to its security holders:  a. None		

We trust you will find the foregoing satisfactory. Should you have further questions or comments, please do not hesitate to contact the undersigned.

Yours truly,

**ANFIELD SUJIR KENNEDY & DURN O**

per: 

Michael Kennedy

MK/jgs

Enclosures

**BC FORM 53-901F (Previously Form 27) *Securities Act* (British Columbia)  
FORM 27 *Securities Act* (Alberta) Under Section 146(1) of the *Securities Act*  
FORM 27 *Securities Act* (Ontario) Under Section 75(2) of the *Act***

**MATERIAL CHANGE REPORT**

**ITEM 1      REPORTING ISSUER**

BioMS Medical Corp.

**ITEM 2      DATE OF MATERIAL CHANGE**

March 18, 2004

**ITEM 3      PRESS RELEASE**

The Issuer issued a press release under the date of March 18, 2004

**ITEM 4 &  
ITEM 5      SUMMARY/FULL DESCRIPTION OF MATERIAL CHANGE:**

The Issuer completed the sale of 2,821,526 units of the Company at a price of \$3.30 per Unit for gross proceeds of \$9,311,000. Each Unit consists of one Class A common share of the Company and one-half of one non-transferable share purchase warrant. Each whole share purchase warrant entitles the holder to purchase one common share at a price of \$4.30 per share on or before March 17, 2005. Union Securities Ltd. acted as agent.

**ITEM 6      RELIANCE ON SECTION 85(2) OF THE *SECURITIES ACT* (BRITISH COLUMBIA), 146(2) OF THE *SECURITIES ACT* (ALBERTA), 75(3) OF THE *SECURITIES ACT* (ONTARIO)**

N/A - This report is not being filed on a confidential basis.

**ITEM 7      OMITTED INFORMATION**

N/A

**ITEM 8      SENIOR OFFICERS**

To obtain further information, contact Kevin A. Giese, President and Chief Executive Officer or Ryan Giese, Corporate Communications, at (780) 413-7152.

**ITEM 9      STATEMENT OF SENIOR OFFICER**

The foregoing accurately discloses the material change referred to herein.

Dated at Vancouver, B.C. this 18th day of March, 2004.

"Michael Kennedy"  
Michael Kennedy /Corporate Secretary



[www.biomsmedical.com](http://www.biomsmedical.com)

**FOR IMMEDIATE RELEASE**

**TSX: MS**

**BioMS MEDICAL ANNOUNCES 17 ADDITIONAL PATENTS FOR MS DRUG**

Edmonton, Alberta, March 23, 2004 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the University of Alberta has received seventeen additional patents for the Company's synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS). BioMS Medical, through a subsidiary, licenses these patents on an exclusive worldwide basis from the University of Alberta.

The additional countries granting patents included Austria, Belgium, the Czech Republic, Denmark, Finland, France, Greece, Germany, Ireland, Luxembourg, Monaco, Netherlands, Spain, Sweden, Switzerland, Ukraine and the United Kingdom. In total, 50 patents have been granted to the University of Alberta for MBP8298 in 29 countries worldwide, including three patents issued in the United States.

"We continue to build a very powerful intellectual property portfolio for our lead product, MBP8298," said Kevin Giese, President of BioMS Medical. "With patent protection in the United States, Canada and many of the key European countries where MS is highly present, the future commercial value of our MS drug is well protected."

**About BioMS Medical Corp.**

BioMS Medical Corp. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies. BioMS Medical's patented MBP8298 technology for the treatment of multiple sclerosis has undergone Phase I and II human clinical trials. The Company has a platform technology, HYC750, involving a method for the potential mobilization of stem cells and neutrophils for the treatment of cancer therapy related side-effects, as well as an interest in BioCyDex, a private company developing platform drug and gene delivery and imaging technology. BioMS trades on the Toronto Stock Exchange under the symbol MS. For further information, please visit our web site at: [www.biomsmedical.com](http://www.biomsmedical.com).

*This news release may contain certain forward-looking statements that reflect the current views and/or expectations of BioMS with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.*

For further information please contact:

Ryan Giese  
Corporate Communications  
(780) 413-7152  
[rgiese@biomsmedical.com](mailto:rgiese@biomsmedical.com)

Tony Hesby  
Vice President of Corporate Affairs  
(780) 413-7152  
[tony.hesby@biomsmedical.com](mailto:tony.hesby@biomsmedical.com)



[www.biomsmedical.com](http://www.biomsmedical.com)

**FOR IMMEDIATE RELEASE**

**TSX: MS**

**BioMS MEDICAL RAISES \$9.3 MILLION TO DEVELOP MS DRUG**

**Edmonton, Alberta, March 18, 2004** – BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has completed the sale of 2,821,526 units of the Company at a price of \$3.30 per Unit for gross proceeds of \$9,311,000. Each Unit consists of one Class A common share of the Company and one-half of one non-transferable share purchase warrant. Each whole share purchase warrant entitles the holder to purchase one common share at a price of \$4.30 per share on or before March 17, 2005. Union Securities Ltd. acted as agent.

"The proceeds from this offering will principally be applied towards the pivotal human clinical trial of our lead drug, MBP8298, for the treatment of multiple sclerosis," said Mr. Kevin Giese, President and CEO.

**About BioMS Medical Corp.**

BioMS Medical Corp. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies. BioMS Medical's patented MBP8298 technology for the treatment of multiple sclerosis has undergone Phase I and II human clinical trials. The Company has a platform technology, HYC750, involving a method for the potential mobilization of stem cells and neutrophils for the treatment of cancer therapy related side-effects, as well as an interest in BioCyDex, a private company developing platform drug and gene delivery and imaging technology. BioMS trades on the Toronto Stock Exchange under the symbol MS. For further information, please visit our web site at: [www.biomsmedical.com](http://www.biomsmedical.com).

**NOT FOR DISTRIBUTION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.**

*This news release may contain certain forward-looking statements that reflect the current views and/or expectations of BioMS with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.*

**For more information, please contact:**

Ryan Giese  
Corporate Communications  
**BioMS Medical Corp.**  
780-413-7152  
780-408-3040 Fax  
E-mail: [rgiese@biomsmedical.com](mailto:rgiese@biomsmedical.com)  
Internet: [www.biomsmedical.com](http://www.biomsmedical.com)

James Smith  
Investor Relations, Toronto  
416-815-0700 ext. 229  
416-815-0080 Fax  
E-mail: [jsmith@equicomgroup.com](mailto:jsmith@equicomgroup.com)

Mr. Barry Mire  
Investor Relations, Quebec and U.S.  
Phone: 514-939-3989  
E-mail: [bmire@renmarkfinancial.com](mailto:bmire@renmarkfinancial.com)